研究单位：[1]Chinese Academy of Medical Sciences, Fuwai Hospital[2]Beijing Chaoyang Hospital affiliated to Capical Medical University,Beijing, Beijing, China, 100020[3]Bei Jing Hospital,Beijing, Beijing, China, 100037[4]Chinese Academy of Medical Sciences, FuWai Hospital,Beijing, Beijing, China, 100037[5]Xuanwu hospital of capital medical university,Beijing, Beijing, China, 100053[6]Peking Union Medical College Hospital,Beijing, Beijing, China, 100730[7]Beijing Pinggu Hospital,Beijing, Beijing, China[8]Lanzhou University Second Hospital,Lanzhou, Gansu, China, 730030[9]Guangdong Cardiovascular Institute,Guangzhou, Guangdong, China, 510080[10]Huizhou Municipal Central Hospital,Huizhou, Guangdong, China, 516001[11]The Second Affiliated Hospital to Medical College Shantou University Guangdong,Shantou, Guangdong, China, 515041[12]Shenzhen Sun Yat-sen Cardiovascular Hospital,Shenzhen, Guangdong, China, 518001[13]The First Affiliated Hospital of Guangxi Medical University,Nanning, Guangxi, China, 530021[14]The First Affiliated Hospital of Guangxi University of Chinese Medicine,Nanning, Guangxi, China, 530023[15]Kailua General Hospital,Tangshan, Hebei, China, 063000[16]The First Affiliated Hospital of Hebei North University,Zhangjiakou, Hebei, China, 075000[17]First affiliated Hospital of Harbin Medical University,Harbin, Heilongjiang, China, 150001[18]Hong xinglong center hospital,Shuangyashan, Heilongjiang, China[19]First Affiliated Hospitalof Zhengzhou University,Zhengzhou, Henan, China, 450000[20]Zhoukou City Central Hospital,Zhoukou, Henan, China, 466000[21]Renmin Hospital of Wuhan University,Wuhan, Hubei, China, 430060[22]Kang Ya Hospita,Yiyang, Hunan, China, 413000[23]The Second Affiliated Hospital of Baotou Medical College,Baotou, Inner Mongolia, China, 014030
The Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients (STEP) is a 2-arm, multi-center, prospective, randomized, open-labeled, blinded-endpoint trial. The purpose of this trial is to test whether a treatment program aimed at reducing systolic blood pressure (SBP) to a lower goal (<130 mmHg, intensive treatment) than currently recommended (<150 mmHg, standard treatment) will reduce CVD risk among persons between 60-80 years of old. Furthermore, this trial will also examine the effect of blood pressure APP management strategy via WeChat network on medication compliance, blood pressure control and CVD benefits.
